دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Front Cover
Sun Joon Moon MD, Kyung-Soo Kim MD, Woo Je Lee MD, Mi Yeon Lee MD, Robert Vigersky MD, Cheol-Young Park MD,Â
doi : 10.1111/dom.14939
Volume25, Issue1
Back Cover
Zekai Wu MD, Maha Lebbar MD, Nadine Taleb MD, Laurent Legault MD, Virginie Messier MS, Rémi Rabasa-Lhoret MD,Â
doi : 10.1111/dom.14115
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
Christophe De Block MD, Clifford Bailey PhD, Carol Wysham MD, Andrea Hemmingway PhD, Sheryl Elaine Allen MD, Jennifer Peleshok PhD,Â
doi : 10.1111/dom.14831
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) receptor agonist approved in the United States as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes and under investigation for use in chronic weight management, major adverse cardiovascular events and the management of other conditions, including heart failure with preserved ejection fraction and obesity and non-cirrhotic non-alcoholic steatohepatitis.
Semaglutide for the treatment of overweight and obesity: A review
Natasha Chidekel Bergmann MD, Melanie J. Davies MD, Ildiko Lingvay MD, Filip K. Knop MD,Â
doi : 10.1111/dom.14863
Obesity is a chronic, relapsing disease associated with multiple complications and a substantial morbidity, mortality and health care burden. Pharmacological treatments for obesity provide a valuable adjunct to lifestyle intervention, which often achieves only limited weight loss that is difficult to maintain.
Global mortality of diabetic foot ulcer: A systematic review and meta-analysis of observational studies
Lihong Chen MD, Shiyi Sun MD, Yunyi Gao MD, Xingwu Ran MD,Â
doi : 10.1111/dom.14840
We systematically searched Medline (PubMed), Embase, Scopus, Web of Science, Cochrane Library, China Science and Technology Journal Database (CQVIP), China National Knowledge Infrastructure, the Chinese Biomedical Literature Database (SinoMed) and Wanfang Data from 1 January 2011 to 31 July 2022.
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study
Bernard H. Charbonnel MD, Hungta Chen PhD, Javier Cid-Ruzafa MD, Andrew Cooper PhD, Peter Fenici MD, Marilia B. Gomes MD, Gabriela L. Saraiva MD, Jesús Medina PhD, Antonio Nicolucci MD, Marina V. Shestakova MD, Iichiro Shimomura MD, Filip Surmont MD, Fengming Tang MS, Jiten Vora MD, Hirotaka Watada MD, Kamlesh Khunti MD, on behalf of the DISCOVER Investigators ,Â
doi : 10.1111/dom.14842
To describe glucose-lowering treatment regimens and glycated haemoglobin (HbA1c) trajectories in individuals with type 2 diabetes (T2D) over 36 months of follow-up from the start of second-line therapy.
Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents
Caroline E. Geisler PhD, Meghan P. Antonellis MS, Wolfgang Trumbauer MS, Jennifer A. Martin MS, Tamer Coskun MD, Ricardo J. Samms PhD, Matthew R. Hayes PhD,Â
doi : 10.1111/dom.14843
To investigate the role of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonists alone or combined with glucagon-like peptide-1 receptor (GLP-1R) agonists to regulate palatable food intake and the role of specific macronutrients in these preferences.
iGlarLixi versus basal plus Rapid-Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real-World study
Rory J. McCrimmon MD, Alice Y.Y. Cheng MD, Gagik Galstyan MD, Khier Djaballah MD, Xuan Li MSc, Mathieu Coudert MSc, Juan P. Frias MD,Â
doi : 10.1111/dom.14844
For people with suboptimally controlled type 2 diabetes (T2D) on basal insulin (BI), guidelines recommend several treatment advancement options. This study compared the clinical effectiveness of once-daily iGlarLixi versus a multiple-injection BI + rapid acting insulin (RAI) regimen in adults with T2D advancing from BI therapy in real-world clinical practice.
Associations of microvascular complications with all-cause death in patients with diabetes and COVID-19: The CORONADO, ABCD COVID-19 UK national audit and AMERICADO study groups
Samy Hadjadj, Pierre-Jean Saulnier, Yue Ruan, Xu Zhu, Renee Pekmezaris, Michel Marre, Jean Michel Halimi, Matthieu Wargny, Rustam Rea, Pierre Gourdy, Bertrand Cariou, Alyson K. Myers, Kamlesh Khunti, for the CORONADO, the ABCD COVID-19 diabetes national audit and AMERICADO investigators ,Â
doi : 10.1111/dom.14845
To provide a detailled analysis of the microvascular burden in patients with diabetes hopitalized for COVD-19.
Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO-Peds trial
R. Paul Wadwa MD, Lori M. Laffel MD, Denise R. Franco MD, Mary Anne Dellva MS, Alastair W. Knights PhD, Robyn K. Pollom ANP,Â
doi : 10.1111/dom.14849
To evaluate the efficacy and safety of ultra-rapid lispro (URLi) versus lispro in a paediatric population with type 1 diabetes (T1D) in a Phase 3, treat-to-target study.
A randomized, double-blind, crossover study of the effect of the fluoroquinolone moxifloxacin on glucose levels and insulin sensitivity in young men and women
Christian R. Juhl MD, Josephine Burgdorf MSc, Cecilie Knudsen MD, Anniek F. Lubberding PhD, Simon Veedfald MD, Jonas L. Isaksen MSc, Bolette Hartmann PhD, Ruth Frikke-Schmidt MD, Thomas Mandrup-Poulsen MD, Jens J. Holst MD, Jørgen K. Kanters MD, Signe S. Torekov PhD,Â
doi : 10.1111/dom.14851
The voltage-gated potassium channel Kv11.1 is important for repolarizing the membrane potential in excitable cells such as myocytes, pancreatic α- and β-cells. Moxifloxacin blocks the Kv11.1 channel and increases the risk of hypoglycaemia in patients with diabetes. We investigated glucose regulation and secretion of glucoregulatory hormones in young people with and without moxifloxacin, a drug known to block the Kv11.1 channel.
Efficacy of intermittent short-term use of a real-time continuous glucose monitoring system in non-insulin–treated patients with type 2 diabetes: A randomized controlled trial
Sun Joon Moon MD, Kyung-Soo Kim MD, Woo Je Lee MD, Mi Yeon Lee MD, Robert Vigersky MD, Cheol-Young Park MD,Â
doi : 10.1111/dom.14852
To evaluate the efficacy of intermittent short-term use of a real-time continuous glucose monitoring (RT-CGM) system in non-insulin–treated patients with type 2 diabetes (T2D) uncontrolled with oral antidiabetic drugs (OADs).
Metabolic profile-based subgroups can identify differences in brain volumes and brain iron deposition
Amanda L. Lumsden, Anwar Mulugeta, Ville-Petteri Mäkinen, Elina Hyppönen,Â
doi : 10.1111/dom.14853
To evaluate associations of metabolic profiles and biomarkers with brain atrophy, lesions, and iron deposition to understand the early risk factors associated with dementia.
All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK
Suping Ling PhD, Francesco Zaccardi PhD, Bogdan Vlacho PharmD, Ping Li PhD, Jordi Real Gatius PhD, Manel Mata-Cases MD, Josep Franch-Nadal MD, Mikhail N. Kosiborod MD, Clare Gillies PhD, Peter Fenici MD, DÃdac Mauricio MD, Baiju R. Shah PhD, Kamlesh Khunti PhD,Â
doi : 10.1111/dom.14856
To understand geographical and temporal patterns in the diabetes gap, the excess mortality risk associated with type 2 diabetes (T2D), in three high-income countries.
Clinical significance of prediabetes, undiagnosed diabetes and diagnosed diabetes on critical outcomes in COVID-19: Integrative analysis from the Japan COVID-19 task force
Takahiro Fukushima MD, Shotaro Chubachi MD, Ho Namkoong MD, Takanori Asakura MD, Hiromu Tanaka MD, Ho Lee MD, Shuhei Azekawa MD, Yukinori Okada MD, Ryuji Koike MD, Akinori Kimura MD, Seiya Imoto PhD, Satoru Miyano PhD, Seishi Ogawa MD, Takanori Kanai MD, Koichi Fukunaga MD, The Japan COVID-19 Task Force ,Â
doi : 10.1111/dom.14857
Diabetes mellitus (DM) is a known risk factor for severe coronavirus disease 2019 (COVID-19), but the clinical impact of undiagnosed diabetes and prediabetes in COVID-19 are unclear particularly in Japan.
Sodium-glucose cotransporter-2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity-score-matched, new-user design study with an active comparator using the IQVIA Medical Research Data UK database
Anuradhaa Subramanian BSc, Krishna Gokhale BSc, Christopher Sainsbury MD, Krishnarajah Nirantharakumar, Konstantinos A. Toulis MD,Â
doi : 10.1111/dom.14858
To conduct a pharmacoepidemiological study to explore the association between sodium-glucose cotransporter-2 (SGLT2) inhibitors and gout in patients with type 2 diabetes mellitus (T2DM).
Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials
Alhassane Diallo MD, Miguel Carlos-Bolumbu MD, Pr Eric Renard MD, Florence Galtier MD,Â
doi : 10.1111/dom.14859
To compare treatment effect sizes between a composite kidney outcome (CKO) and three-point major adverse cardiovascular event (MACE-3) outcomes with use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), and to investigate the relationship between treatment effects on CKO and MACE-3 in patients with type 2 diabetes (T2D).
Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function
Lorenzo Nesti MD, Nicola Riccardo Pugliese PhD, Martina Chiriacò MD, Domenico Trico MD, Simona Baldi PhD, Andrea Natali MD,Â
doi : 10.1111/dom.14861
To investigate the impact of epicardial adipose tissue (EAT) thickness on cardiopulmonary performance in patients with type 2 diabetes (T2D) and normal heart function.
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
João Sérgio Neves MD, Francisco Vasques-Nóvoa MD, Marta Borges-Canha MD, Ana Rita Leite MD, Abhinav Sharma MD, Davide Carvalho MD, Milton Packer MD, Faiez Zannad MD, Adelino Leite-Moreira MD, João Pedro Ferreira MD,Â
doi : 10.1111/dom.14862
To perform a post hoc analysis of the FIGHT trial, evaluating the effect of liraglutide (vs. placebo) on the totality of events in patients with heart failure with reduced ejection fraction (HFrEF).
Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial
Rosalie A. Scholtes MD, Charlotte M. Mosterd MD, Anne C. Hesp MD, Mark M. Smits PhD, Hiddo J. L. Heerspink PhD, Daniël H. van Raalte PhD,Â
doi : 10.1111/dom.14864
To study the effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin, the angiotensin receptor blocker (ARB) losartan, and their combination on blood pressure, while studying the mechanisms potentially involved.
Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
Lee-Ling Lim PhD, Eric S. H. Lau PhD, Johnny T. K. Cheung BSc, Siew Pheng Chan MBBS, Linong Ji MD, Soo Lim MD, Sirinart Sirinvaravong MD, A. G. Unnikrishnan MD, Andrea O. Y. Luk MD, Viviana Cortese MD, Alexandra Durocher PharmD, Juliana C. N. Chan MD,Â
doi : 10.1111/dom.14865
To explore the patterns of use of oral glucose-lowering drugs (OGLDs) in Asian patients with type 2 diabetes (T2D), focusing on sulphonylureas (SUs), and to describe patient profiles according to treatment regimen.
Cross-sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes
Taiki Sugimoto PhD, Haruhiko Tokuda MD, Hisayuki Miura MD, Shuji Kawashima MD, Takafumi Ando PhD, Yujiro Kuroda PhD, Nanae Matsumoto PhD, Kosuke Fujita PhD, Kazuaki Uchida MS, Yoshinobu Kishino MD, Takashi Sakurai MD,Â
doi : 10.1111/dom.14866
To examine the association between continuous glucose monitoring (CGM)-derived metrics and cognitive performance in older adults with type 2 diabetes (T2D).
External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial
Amir Razaghizad MSc, Abhinav Sharma MD, Jiayi Ni MSc, João Pedro Ferreira MD, William B. White MD, Cyrus R. Mehta PhD, George L. Bakris MD, Faiez Zannad MD,Â
doi : 10.1111/dom.14867
The Thrombolysis in Myocardial Infarction Risk Score for Heart Failure (HF) in Diabetes (TRS-HFDM) prognosticates HF hospitalization in people with type 2 diabetes (T2D). This study aimed to externally validate and extend its use for those with recent acute coronary syndrome (ACS).
Real-world effectiveness and safety of insulin glargine 300 U/ml in insulin-naïve people with type 2 diabetes in the Latin America region: A subgroup analysis of the ATOS
Hernando Vargas-Uricoechea MSc, José Luis Burga Nuñez MD, Juan Rosas Guzmán MD, Liliana Silva-Gomez MD, Sergio Beltran MD, MarÃa Elena Sañudo-Maury MD,Â
doi : 10.1111/dom.14868
To evaluate the real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in achieving glycaemic goals in insulin-naïve people with type 2 diabetes (T2D) in Mexico, Colombia and Peru (Latin America region) in the A Toujeo Observational Study (ATOS).
Mendelian randomization identifies age at menarche as an independent causal effect factor for gestational diabetes mellitus
Likui Lu PhD, Bangbei Wan PhD, Miao Sun PhD,Â
doi : 10.1111/dom.14869
The relationship between age at menarche (AAM) and gestational diabetes mellitus (GDM) risk is still inconclusive. This Mendelian randomization (MR) analysis was used to assess systematically the causal relationship between AAM and GDM risk in human beings.
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study
Thomas Nyström MD, Emilie Toresson Grip MSc, Joel Gunnarsson MSc, Paula Casajust MSc, Kristina Karlsdotter PhD, Josefin Skogsberg PhD, Anastasia Ustyugova MD, on behalf of EMPRISE Study Group ,Â
doi : 10.1111/dom.14870
To evaluate effectiveness and healthcare resource utilization (HCRU) of empagliflozin versus dipeptidyl peptidase-4 inhibitors (DPP-4i) in Swedish clinical practice, as part of the EMPRISE EU study (EUPAS27606, NCT03817463).
Saxagliptin combined with additional oral antihyperglycaemic agents in drug-naive diabetic patients with high glycosylated haemoglobin: A 24-week, multicentre, randomized, open-label, active parallel-controlled group clinical trial in China (SUCCESS)
Xiaoping Chen MD, Hongwei Jiang MD, Hongmei Li MD, Hongyu Kuang MD, Li Chen MD, Jianhua Ma MD, Qiu Zhang MD, Tianrong Pan MD, Wenying Yang MD, on behalf of SUCCESS study investigators ,Â
doi : 10.1111/dom.14873
To assess the efficacy and safety of a dipeptidyl peptidase-4 (DPP-4) inhibitor combined respectively with three oral antihyperglycaemic agents in Chinese patients with newly diagnosed type 2 diabetes mellitus (T2DM) with high levels of glycated haemoglobin (HbA1c).
Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment for people with type 2 diabetes in England: A cross-sectional study
Patrick Bidulka MSc, Rohini Mathur PhD, David G. Lugo-Palacios PhD, Stephen O'Neill PhD, Anirban Basu PhD, Richard J. Silverwood PhD, Paul Charlton MA, Andrew Briggs DPhil, Liam Smeeth MBChB, Amanda I. Adler MD, Ian J. Douglas PhD, Kamlesh Khunti MD, Richard Grieve PhD,Â
doi : 10.1111/dom.14874
To assess any disparities in the initiation of second-line antidiabetic treatments prescribed among people with type 2 diabetes mellitus (T2DM) in England according to ethnicity and social deprivation level.
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults
Yuan-Di Halvorsen PhD, John Paul Lock MD, Juan P. Frias MD, Francisco José Tinahones MD, Dominik Dahl MD, Annie L. Conery PhD, Mason W. Freeman MD,Â
doi : 10.1111/dom.14875
To compare the effects of bexagliflozin tablets 20 mg, with those of optimally titrated glimepiride when used to treat adults with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin.
Impaired awareness of hypoglycaemia: Prevalence and associated factors before and after FreeStyle Libre use in the Association of British Clinical Diabetologists audit
Beatrice Pieri MBBS, Harshal Deshmukh PhD, Emma G. Wilmot PhD, Pratik Choudhary MD, Najeeb Shah MRCP, Robert Gregory DM, Dennis Barnes FRCP, Simon Saunders MD, Jane Patmore FRCP, Chris Walton FRCP, Robert E. J. Ryder MD, Thozhukat Sathyapalan MD,Â
doi : 10.1111/dom.14841
Insulin degludec/insulin aspart safely improves HbA1c: A long-term real-world cohort study (IDEA)
Jothydev Kesavadev MD, Banshi Saboo MD, Rajiv Kovil MBBS, Shashank Joshi MD, Arun Shankar MBBS, Asha Ashik MD, Ashwin David Ashok MBBS, Anjana Basanth MSc, Gopika Krishnan MBA,Â
doi : 10.1111/dom.14847
Comparing dual-hormone and single-hormone automated insulin delivery systems on nocturnal glucose management among children and adolescents with type 1 diabetes: A pooled analysis
Zekai Wu MD, Maha Lebbar MD, Nadine Taleb MD, Laurent Legault MD, Virginie Messier MS, Rémi Rabasa-Lhoret MD,Â
doi : 10.1111/dom.14850
Severe acute respiratory syndrome coronavirus 2 spike antibody level decline is more pronounced after the second vaccination, but response to the third vaccination is similar in people with type 1 and type 2 diabetes compared with healthy controls: The prospective COVAC-DM cohort study
Caren Sourij MD, Faisal Aziz MSc, Harald Kojzar BSc, Anna M. Obermayer MD, Christoph Sternad, Alexander Müller MSc, Norbert J. Tripolt PhD, Peter N. Pferschy MSc, Felix Aberer MD, Peter Schlenke MD, Barbara Kleinhappl, Martin Stradner MD, Nazanin Sareban MD, Martina Moritz MD, Margarita Dominguez-Villar PhD, Nick Oliver MD, Ivo Steinmetz MD, Harald Sourij MD,Â
doi : 10.1111/dom.14855
Type 1 diabetes iron-deficiency anaemia case report and the clinical relevance of red blood cell lifespan-adjusted glycated haemoglobin
Yushi Hirota, Yongjin Xu, Akane Yamamoto, Atsuko Matsuoka, Timothy C. Dunn, Wataru Ogawa,Â
doi : 10.1111/dom.14860
